"Addressing Corporate Control in Public Health Vaccine Development"

The current system of public health vaccine creation is flawed, with corporations like GSK gaining control of products developed with government and nonprofit funding. GSK's decision to stall the development of a potentially lifesaving tuberculosis vaccine in favor of more profitable ones is a stark example of this issue. The company has retained control of the adjuvant, a key ingredient, limiting its availability. This lack of transparency and prioritization of profits over public health needs is concerning. It is crucial to implement a system where corporations pay royalties when government funding is used in the development of their products. This would ensure that public health needs are prioritized and that the benefits of government-funded research are shared more equitably.